好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mode of Delivery on Postpartum Well-being for Women with Multiple Sclerosis
Multiple Sclerosis
P12 - Poster Session 12 (11:45 AM-12:45 PM)
1-007

To evaluate the relationship between mode of delivery and postpartum well-being in women with multiple sclerosis (MS).

Women with neurological conditions, including MS, experience elevated morbidity postpartum. In the general population, depression, sleep disturbance, and fatigue tend to worsen during the postpartum period, and especially following caesarean section (CS) compared with vaginal delivery (VD). Though women with MS have higher risk of these symptoms at baseline, the impact of delivery mode remains unexplored.

This is an analysis of a prospective cohort of 41 cis-women with MS from a single academic center who delivered via CS (n=12) or VD (n=29) between 2018 and 2022. Symptoms were assessed one month after delivery using self-reported questionnaires for sleep [Medical Outcomes Study—Sleep Scale (MOS-SS)], fatigue [Epworth Sleepiness Scale (ESS) and Modified Fatigue Impact Scale (MFIS)], and depression [Edinburgh Postnatal Depression Scale (EPDS)]. Scores were compared using two-sample t-tests for continuous variables; significance level was <0.05.

The main demographic and MS characteristics of the women delivering via CS were similar to those delivering via VD, although more were primiparous (P=0.05). Women with CS reported better sleep adequacy (MOS-SS, P=0.0015), reduced daytime sleepiness (ESS, P=0.017), and decreased fatigue (MFIS, P=0.049, particularly the cognitive fatigue sub-scale, (P=0.032) relative to women with VD. Postpartum depression was not associated with delivery mode.

Surprisingly, women with MS who delivered via CS reported better well-being postpartum relative to those delivering vaginally. Given the significant and added burden of MS and symptom management faced postpartum by women with MS, CS could represent a “forced rest,” paradoxically improving well-being. Further research is necessary to evaluate this and other possible mechanisms underlying this association. Overall, the current findings highlight the need for tailored postpartum care strategies to improve the well-being of these patients.

Authors/Disclosures
Tiffany Cao, Medical Student
PRESENTER
Ms. Cao has nothing to disclose.
Annika Anderson (UCLA David Geffen School of Medicine) Miss Anderson has nothing to disclose.
Ayushi D. Balan (UCSF) Miss Balan has nothing to disclose.
Stephanie Hsu Stephanie Hsu has nothing to disclose.
Min Ji Kim, BA Ms. Kim has nothing to disclose.
Maria K. Houtchens, MD Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serono. Dr. Houtchens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Cravath. Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Beasley . Dr. Houtchens has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Biogen. The institution of Dr. Houtchens has received research support from Genzyme. The institution of Dr. Houtchens has received research support from Biogen. The institution of Dr. Houtchens has received research support from Genentech. The institution of Dr. Houtchens has received research support from Novartis.
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.